Abstract
Malignant pleural mesothelioma (MPM) is often treated with combination chemotherapy with a platin compound and a folate antagonist being the recommended treatment of patients with advance disease. Patients with potentially operable MPM can be offered the benefit of a more radical multimodality approach including neoadjuvant chemotherapy and extrapleural pneumonectomy (EPP) without major long-term impairment of their quality of life and survival.